Solskin
- Johnson & Johnson (NYSE:JNJ) on Monday reported new findings from an indirect treatment comparison of its FcRn blocker, nipocalimab, marketed as Imaavy, for generalized myasthenia gravis in adults.
- The analysis, which draws from a late-stage study, reveals that patients experienced similar relief from symptoms as early as Week 1.
- Furthermore, Imaavy demonstrated sustained disease control, showing significant improvements in MG-ADLa scores compared to the Phase 3 results of other FcRn blockers at various points throughout a 24-week treatment period.
- Imaavy is currently approved in the U.S. for use in both adult and pediatric patients aged 12 and older who test positive for either anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.
More on J&J
- Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
- Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
- Johnson & Johnson (JNJ) Presents at the Bernstein’s 41st Annual Strategic Decisions Conference (Transcript)
- J&J, AbbVie get EU endorsement for Imbruvica’s expanded approval
- Lower interest rates, drug pricing reform clarity are catalysts for biotech M&A market